hereby submits the following Freedom of Information request with regards to the Marketing Authorisations for Revolade 25 mg, 50 mg and 75 mg film-coated tablets (PLGB 00101/1126-1128-1129) held by Novartis Pharmaceuticals UK Limited. The details of the request are as follows: * The Environmental Risk Assessment document named Revolade(r) (eltrombopag olamine) 25 and 50 mg film coated tablets Environmental Risk Assessment and associated study/chemical testing reports that are currently registered in module 1.6 for the following Product Licences (PLGB 00101/1126, PLGB 00101/1128, PLGB 00101/1129) In accordance with the Heads of Medicines Agencies/European Medicines Agency (HMA/EMA) guidance on transparency, the environmental risk assessment information within module 1.6 requested is considered releasable, as outlined in pages 5 and 25 of the HMA/EMA guidance.